skip to primary navigationskip to content

Cambridge Institute for Medical Research

Department A-Z

Our strategy

We aim to create an inspiring environment in which outstanding scientists can excel. By providing state-of-the-art core facilities and support for our researchers, we foster new collaborations that spark discoveries about fundamental cellular processes and their relevance in disease.

Read more

Research advances

In eLife, the Nathan lab uncover a new pathway linking the V-ATPase proton pump with iron metabolism to regulate stabilization of the hypoxia-inducible transcription factor HIF1a.

Read more

Cambridge Science Festival

Join our researchers for hands-on activities at the Guildhall this weekend (March 18 and 19).

Read more

Incredible Medicine

Geoff Woods discusses his research on those rare individuals who are born unable to feel pain in the BBC2 series on Incredible Medicine.

Read more

International Women's Day 2017

Lucy Raymond reflects on this 'ordinary' day in the lab.

Read more

Potential haemophilia treatment

£14 million Series A funding has been secured for ApcinteX Limited, a spin-out arising from a collaboration between Jim Huntington (CIMR) and Trevor Baglin (Addenbrooke's) to develop a new treatment for haemophilia.

Read more

A unique partnership between basic and clinical research, aiming to understand the cellular basis of disease

New publications


Read lab (PNAS 2017)

Predicting crystal structure success.


Maxwell lab (PLoS Genet. 2017)

Altered mitochondrial RNA translation in kidney disease.


Rubinsztein lab (Neuron 2017)

Autophagy in neuronal health and disease.


Buss lab (PNAS 2017)

Cytoskeletal control by myosin VI motor directionality.


Lehner and Weekes labs (eLife 2017)

Mechanisms of NK cell suppression by HCMV.


Raymond lab (Nature Genet. 2016)

Identification of a KMT2B-linked movement disorder.